Study On Pharmacodynamics Of The Compound Laggera Pterodonta(DC.) Against Influenza Virus

Objective:The pharmacodynamics of the Compound Laggera pterodonta(DC.)against influenza virus in vitro and vivo.Methods:1.The cytotoxicity of Laggera pterodonta(DC.)mixture was measured with MTT assay.Two modes of administration were adopted:prevention mode and treatment mode,and cytopathic inhibition method(CPE assay)was used to observe the antiviral effection of the drug in vitro.2.A mouse model of influenza virus pneumonia was 2.to test the antiviral effect of compound Laggera pterodonta(DC.)mixture in vivo.3.real-time fluorescence quantitative PCR technique was used to detect the effect of the cell-compound Laggera pterodonta(DC.)on the expression level of cells,chemokine messenger RNA(m RNA)induced by influenza virus.Results:1.There is no obvious anti-influenza effect on the MDCK cells infected with H1N1 virus at different Compound Laggera pterodonta concentrations.2.Divide the mice into High-dose group Medium-dose group Low-dose group.The results of mice model in vivo showed that the Compound Laggera pterodonta can decrease the lung index.3.The Compound Laggera pterodonta can obviously inhibit the A549 cells1 mRNA expression of IL-6,IL-8,Cox-2,IFN-? and CCL5 after influenza A H1N1 virus infection at two concentrations of 0.25mg/ml and 0.5mg/ml.At the concentrations of 0.25mg/ml,Compound Laggera pterodonta also had a significant inhibitory effect in mRNA expression of MCP-1(P<0.01).Conclusions:The compound Laggera pterodonta in vitro experimental effect is not obvious,but it can significantly improve the lung index of the virus model mice and have a significant inhibitory effect on inflammatory factors.This may be because the drug does not directly affect the virus itself,but plays an anti-influenza role by regulating the body's immune response function.